Search

Your search keyword '"Primary prophylactic ICD"' showing total 4 results
Start Over Descriptor "Primary prophylactic ICD" Publisher elsevier
4 results on '"Primary prophylactic ICD"'

1. Nocturnal respiratory rate predicts ICD benefit: A prospective, controlled, multicentre cohort study

Author

Michael Dommasch, Alexander Steger, Petra Barthel, Katharina M Huster, Alexander Müller, Daniel Sinnecker, Karl-Ludwig Laugwitz, Thomas Penzel, Andrzej Lubinski, Panagiota Flevari, Markus Harden, Tim Friede, Stefan Kääb, Bela Merkely, Christian Sticherling, Rik Willems, Heikki V. Huikuri, Axel Bauer, Marek Malik, Markus Zabel, and Georg Schmidt

Subjects
Nocturnal respiratory rate, Primary prophylactic ICD, Benefit prediction, Medicine (General), R5-920
Abstract

Background: Implantable cardioverter defibrillators (ICDs) prevent sudden cardiac death. ICD implantation decisions are currently based on reduced left ventricular ejection fraction (LVEF≤35%). However, in some patients, the non-arrhythmic death risk predominates thus diminishing ICD-therapy benefits. Based on previous observations, we tested the hypothesis that compared to the others, patients with nocturnal respiratory rate (NRR) ≥18 breaths per minute (brpm) benefit less from prophylactic ICD implantations. Methods: This prospective cohort study was a pre-defined sub-study of EU-CERT-ICD trial conducted at 44 centers in 15 EU countries between May 12, 2014, and September 6, 2018. Patients with ischaemic or non-ischaemic cardiomyopathy were included if meeting primary prophylactic ICD implantation criteria. The primary endpoint was all-cause mortality. NRR was assessed blindly from pre-implantation 24-hour Holters. Multivariable models and propensity stratification evaluated the interaction between NRR and the ICD mortality effect. This study is registered with ClinicalTrials.gov (NCT0206419). Findings: Of the 2,247 EU-CERT-ICD patients, this sub-study included 1,971 with complete records. In 1,363 patients (61.7 (12) years; 244 women) an ICD was implanted; 608 patients (63.2 (12) years; 108 women) were treated conservatively. During a median 2.5-year follow-up, 202 (14.8%) and 95 (15.6%) patients died in the ICD and control groups, respectively. NRR statistically significantly interacted with the ICD mortality effect (p = 0.0070). While the 1,316 patients with NRR

Published
2021
Full Text
View/download PDF

2. Nocturnal respiratory rate predicts ICD benefit:a prospective, controlled, multicentre cohort study

Abstract

Background: Implantable cardioverter defibrillators (ICDs) prevent sudden cardiac death. ICD implantation decisions are currently based on reduced left ventricular ejection fraction (LVEF≤35%). However, in some patients, the non-arrhythmic death risk predominates thus diminishing ICD-therapy benefits. Based on previous observations, we tested the hypothesis that compared to the others, patients with nocturnal respiratory rate (NRR) ≥18 breaths per minute (brpm) benefit less from prophylactic ICD implantations. Methods: This prospective cohort study was a pre-defined sub-study of EU-CERT-ICD trial conducted at 44 centers in 15 EU countries between May 12, 2014, and September 6, 2018. Patients with ischaemic or non-ischaemic cardiomyopathy were included if meeting primary prophylactic ICD implantation criteria. The primary endpoint was all-cause mortality. NRR was assessed blindly from pre-implantation 24-hour Holters. Multivariable models and propensity stratification evaluated the interaction between NRR and the ICD mortality effect. This study is registered with ClinicalTrials.gov (NCT0206419). Findings: Of the 2,247 EU-CERT-ICD patients, this sub-study included 1,971 with complete records. In 1,363 patients (61.7 (12) years; 244 women) an ICD was implanted; 608 patients (63.2 (12) years; 108 women) were treated conservatively. During a median 2.5-year follow-up, 202 (14.8%) and 95 (15.6%) patients died in the ICD and control groups, respectively. NRR statistically significantly interacted with the ICD mortality effect (p = 0.0070). While the 1,316 patients with NRR<18 brpm showed a marked ICD benefit on mortality (adjusted HR 0.529 (95% CI 0.376–0.746); p = 0.0003), no treatment effect was demonstrated in 655 patients with NRR≥18 brpm (adjusted HR 0.981 (95% CI 0.669–1.438); p = 0.9202). Interpretation: In the EU-CERT-ICD trial, patients with NRR≥18 brpm showed limited benefit from primary prophylactic ICD implantation. Those with NRR<18 brpm benefi

Published
2021

3. Nocturnal respiratory rate predicts ICD benefit:a prospective, controlled, multicentre cohort study

Author

Dommasch, M. (Michael), Steger, A. (Alexander), Barthel, P. (Petra), Huster, K. M. (Katharina M.), Müller, A. (Alexander), Sinnecker, D. (Daniel), Laugwitz, K.-L. (Karl-Ludwig), Penzel, T. (Thomas), Lubinski, A. (Andrzej), Flevari, P. (Panagiota), Harden, M. (Markus), Friede, T. (Tim), Kääb, S. (Stefan), Merkely, B. (Bela), Sticherling, C. (Christian), Willems, R. (Rik), Huikuri, H. V. (Heikki V.), Bauer, A. (Axel), Malik, M. (Marek), Zabel, M. (Markus), Schmidt, G. (Georg), and T. E. (The EU-CERT-ICD investigators)

Subjects
Benefit prediction, Nocturnal respiratory rate, Primary prophylactic ICD
Abstract

Background: Implantable cardioverter defibrillators (ICDs) prevent sudden cardiac death. ICD implantation decisions are currently based on reduced left ventricular ejection fraction (LVEF≤35%). However, in some patients, the non-arrhythmic death risk predominates thus diminishing ICD-therapy benefits. Based on previous observations, we tested the hypothesis that compared to the others, patients with nocturnal respiratory rate (NRR) ≥18 breaths per minute (brpm) benefit less from prophylactic ICD implantations. Methods: This prospective cohort study was a pre-defined sub-study of EU-CERT-ICD trial conducted at 44 centers in 15 EU countries between May 12, 2014, and September 6, 2018. Patients with ischaemic or non-ischaemic cardiomyopathy were included if meeting primary prophylactic ICD implantation criteria. The primary endpoint was all-cause mortality. NRR was assessed blindly from pre-implantation 24-hour Holters. Multivariable models and propensity stratification evaluated the interaction between NRR and the ICD mortality effect. This study is registered with ClinicalTrials.gov (NCT0206419). Findings: Of the 2,247 EU-CERT-ICD patients, this sub-study included 1,971 with complete records. In 1,363 patients (61.7 (12) years; 244 women) an ICD was implanted; 608 patients (63.2 (12) years; 108 women) were treated conservatively. During a median 2.5-year follow-up, 202 (14.8%) and 95 (15.6%) patients died in the ICD and control groups, respectively. NRR statistically significantly interacted with the ICD mortality effect (p = 0.0070). While the 1,316 patients with NRR

Published
2021

4. Nocturnal respiratory rate predicts ICD benefit: A prospective, controlled, multicentre cohort study

Author

Georg Schmidt, Stefan Kääb, Michael Dommasch, Thomas Penzel, Markus Zabel, Andrzej Lubiński, Tim Friede, Katharina M. Huster, Alexander Steger, Karl-Ludwig Laugwitz, Axel Bauer, Béla Merkely, Panagiota Flevari, Marek Malik, Petra Barthel, Daniel Sinnecker, Heikki V. Huikuri, Markus Harden, Christian Sticherling, Alexander Müller, and Rik Willems

Subjects
medicine.medical_specialty, Respiratory rate, Cardiomyopathy, 01 natural sciences, Sudden cardiac death, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Clinical endpoint, Medicine, 030212 general & internal medicine, 0101 mathematics, Prospective cohort study, lcsh:R5-920, Ejection fraction, Benefit prediction, business.industry, 010102 general mathematics, General Medicine, medicine.disease, Nocturnal respiratory rate, 3. Good health, Icd implantation, ddc, lcsh:Medicine (General), business, Cohort study, Research Paper, Primary prophylactic ICD
Abstract

BACKGROUND: Implantable cardioverter defibrillators (ICDs) prevent sudden cardiac death. ICD implantation decisions are currently based on reduced left ventricular ejection fraction (LVEF≤35%). However, in some patients, the non-arrhythmic death risk predominates thus diminishing ICD-therapy benefits. Based on previous observations, we tested the hypothesis that compared to the others, patients with nocturnal respiratory rate (NRR) ≥18 breaths per minute (brpm) benefit less from prophylactic ICD implantations. METHODS: This prospective cohort study was a pre-defined sub-study of EU-CERT-ICD trial conducted at 44 centers in 15 EU countries between May 12, 2014, and September 6, 2018. Patients with ischaemic or non-ischaemic cardiomyopathy were included if meeting primary prophylactic ICD implantation criteria. The primary endpoint was all-cause mortality. NRR was assessed blindly from pre-implantation 24-hour Holters. Multivariable models and propensity stratification evaluated the interaction between NRR and the ICD mortality effect. This study is registered with ClinicalTrials.gov (NCT0206419). FINDINGS: Of the 2,247 EU-CERT-ICD patients, this sub-study included 1,971 with complete records. In 1,363 patients (61.7 (12) years; 244 women) an ICD was implanted; 608 patients (63.2 (12) years; 108 women) were treated conservatively. During a median 2.5-year follow-up, 202 (14.8%) and 95 (15.6%) patients died in the ICD and control groups, respectively. NRR statistically significantly interacted with the ICD mortality effect (p = 0.0070). While the 1,316 patients with NRR

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results